Content about Methotrexate

January 15, 2014

A new drug for autoimmune diseases from Antares Pharma that the company calls the first of its kind is now available, the drug maker said Wednesday.

EWING, N.J. — A new drug for autoimmune diseases from Antares Pharma that the company calls the first of its kind is now available, the drug maker said Wednesday.

Antares announced the availability of Otrexup for rheumatoid arthritis and psoriasis in adults and polyarticular idiopathic arthritis in children. The company said the drug is the first Food and Drug Administration-approved subcutaneous methotrexate product for once-weekly self-administration. Otrexup, which the FDA approved in October, is available with a single-dose auto injector.

October 24, 2013

The Food and Drug Administration has approved a new formulation of a drug made by Genentech for rheumatoid arthritis that can be injected into the skin.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a new formulation of a drug made by Genentech for rheumatoid arthritis that can be injected into the skin.

Genentech announced the approval of a subcutaneous formulation of Actemra (tocilizumab) in adults for adults with moderate RA who have not found sufficient relief by taking such disease-modifying antirheumatic drugs as methotrexate. Like the intravenous formulation of Actemra, the new version can be used alone or with drugs like methotrexate.

October 14, 2013

The Food and Drug Administration has approved a new drug made by Antares Pharma for treating rheumatoid arthritis and psoriasis, the drug maker said Monday.

EWING, N.J. — The Food and Drug Administration has approved a new drug made by Antares Pharma for treating rheumatoid arthritis and psoriasis, the drug maker said Monday.

November 6, 2012

The Food and Drug Administration has approved a drug for rheumatoid arthritis ahead of the day the agency was scheduled to decide whether or not to approve it, the agency said Tuesday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug for rheumatoid arthritis ahead of the day the agency was scheduled to decide whether or not to approve it, the agency said Tuesday.

June 14, 2012

Cellceutix on Wednesday reported that the Food and Drug Administration granted a section 505(b) designation for its Prurisol treatment for psoriasis, which would allow the company to forgo early-stage trials and advance Prurisol into latter-stage clinical trials.

BEVERLY, Mass. — Cellceutix on Wednesday reported that the Food and Drug Administration granted a section 505(b) designation for its Prurisol treatment for psoriasis, which would allow the company to forgo early-stage trials and advance Prurisol into latter-stage clinical trials.

May 4, 2012

The number of new drug shortages has been halved as early notifications from manufacturers of potential shortages have increased sixfold, the commissioner of the Food and Drug Administration wrote Thursday.

SILVER SPRING, Md. — The number of new drug shortages has been halved as early notifications from manufacturers of potential shortages have increased sixfold, the commissioner of the Food and Drug Administration wrote Thursday.

February 21, 2012

The Food and Drug Administration's action to address the ongoing shortage of certain cancer drugs has garnered praise from a group representing the manufacturers and distributors of generic pharmaceuticals.

WASHINGTON — The Food and Drug Administration's action to address the ongoing shortage of certain cancer drugs has garnered praise from a group representing the manufacturers and distributors of generic pharmaceuticals.

The Generic Pharmaceutical Association said it applauded the FDA's action to address the shortage of cancer drugs Doxil (doxorubicin hydrochloride liposome injection) and preservative-free methotrexate. GPhA also added that generic drug manufacturers are tirelessly working with regulators to provide needed supplies of the critical medicines.

May 11, 2011

Patients with moderate to severe rheumatoid arthritis who respond to 12 weeks of treatment with a drug made by UCB are more likely to show improvement in their condition in the long run, according to results of a study published in the Journal of Rheumatology.

BRUSSELS — Patients with moderate to severe rheumatoid arthritis who respond to 12 weeks of treatment with a drug made by UCB are more likely to show improvement in their condition in the long run, according to results of a study published in the Journal of Rheumatology.

November 7, 2010

Patients with rheumatoid arthritis derive about as much benefit from a weekly injection of a...

NEW YORK Patients with rheumatoid arthritis derive about as much benefit from a weekly injection of a biotech drug made by Bristol-Myers Squibb for the disease as they do from receiving it via IV on a monthly basis, according to late-stage clinical trial data released Monday.

September 29, 2010

The biotech division of Johnson & Johnson is hoping to expand the use of a...

HORSHAM, Pa. The biotech division of Johnson & Johnson is hoping to expand the use of a treatment for autoimmune disorders.

 

Centocor Ortho Biotech said it had filed an application with the Food and Drug Administration to get approval for Simponi (golimumab) to stop the progression of structural damage, induce major clinical response, maintain reductions in signs and symptoms, and improve physical function in the treatment of rheumatoid arthritis.

 

 

January 10, 2010

The Food and Drug Administration has approved a Genentech drug for treating rheumatoid arthritis, the...